Non-viable Lactobacillus Reuteri DSMZ 17648 (Pylopass™) As A New Approach To Helicobacter Pylori Control In Humans
Notes for this study:
|Number of Subjects
In a single blind study where after two weeks placebo in both groups there was then either a continuation of placebo or administration of _L. reuteri_ for two weeks, supplementation of the DSMZ 17648 strain at 2x10^10^ CFU daily was able to significantly reduce breath urea in _H. pylori_ infected persons who did not reach the criteria for eradication therapy.
The benefits of two weeks supplementation persisted for 24 weeks, and there was no difference in potency between freeze-dried and spray-dried bacteria.